Skip to main content
NVDA+0.53%AAPL-0.87%GOOGL-1.59%MSFT-0.95%AMZN-1.89%TSM-0.99%SPCX-1.90%META+1.06%AVGO-0.96%TSLA+0.45%SKHY-0.24%BRK-B-0.01%LLY+0.55%MU+0.59%JPM-1.36%WMT-0.14%AMD+1.97%V-0.45%XOM+2.27%JNJ-0.98%ASMLa-1.22%0700.HK+1.90%MA-0.61%INTC+1.07%ABBV+0.31%1398.HK-2.09%CSCO+0.62%CVX+1.81%BAC-0.33%ORCL-1.01%COST-1.10%KO-0.98%DELL+3.86%CAT-0.38%HSBA.L-2.08%0005.HK-3.21%PG+0.41%UNH-1.56%LRCX-2.25%AP2d-2.19%AMAT-1.10%1816.HK-0.46%3988.HK-2.13%NFLX-2.73%GE-2.73%MS-1.88%0857.HK+0.60%HD-1.47%PM-0.25%0939.HK-2.83%USDJPY+1.02%NZDUSD-0.94%CHFJPY+0.78%USDTHB+0.71%GBPJPY+0.69%CADJPY+0.68%GBPNZD+0.64%NZDCHF-0.62%NZDCAD-0.61%AUDUSD-0.57%EURJPY+0.51%EURUSD-0.48%AUDJPY+0.47%EURNZD+0.47%PLNJPY+0.44%NOKJPY+0.43%GBPTRY+0.41%AUDNZD+0.38%USDCAD+0.33%NZDMXN-0.33%USDCHF+0.33%GBPHKD+0.32%SGDJPY+0.32%GBPUSD-0.31%GBPMXN-0.28%USDTRY+0.25%GBPAUD+0.24%AUDCHF-0.23%AUDCAD-0.22%USDSEK+0.21%USDSGD+0.19%EURCAD-0.17%USDILS+0.16%EURSEK+0.16%EURGBP-0.15%NZDSGD-0.15%EURCHF-0.14%EURSGD+0.14%GBPZAR-0.14%CHFNOK-0.13%EURCZK+0.11%EURAUD+0.10%USDNOK+0.08%AUDDKK-0.08%NZDJPY+0.08%USDCNH+0.07%USDPLN+0.07%GBPSGD+0.07%EURZAR-0.07%AUDSGD+0.06%AUDNOK-0.05%USDDKK+0.05%EURHKD-0.04%USDCOP-0.04%GBPCAD+0.03%EURNOK+0.03%CHFSGD-0.02%CADCHF-0.02%USDHKD+0.02%USDMXN+0.02%EURPLN+0.02%USDZAR-0.01%EURDKK-0.01%CHFSEK-0.01%EURCNH0.00%GBPCHF0.00%USOIL+2.54%W1+1.74%UKOIL+1.60%SUGAR-1.49%XNGUSD+1.25%COFFEE-1.07%COCOA-1.02%C1+1.01%S1+0.89%HG1+0.42%XAUUSD-0.30%GAUUSD-0.30%BTCUSD-2.73%ETHUSD-4.03%USDTUSD-0.03%XRPUSD-2.45%SOLUSD-3.23%TRXUSDT-0.44%ZECUSDT-3.95%DOGEUSD-2.29%XMRUSDT+0.75%LINKUSD-2.60%XLMUSD+0.50%BCHUSDT-1.43%UNIUSD-3.14%LTCUSD-2.62%HBARUSDT-0.18%TONUSD+26.79%SUIUSD-2.62%TAOUSDT-3.30%AAVEUSD-2.37%DOTUSDT-2.21%ICPUSDT-7.23%ONDOUSDT-3.37%WLDUSDT-1.56%ARBUSDT+4.73%ATOMUSDT-1.85%JUPUSDT-4.30%INJUSDT-9.68%STXUSDT-3.11%FETUSDT-4.35%PYTHUSDT-4.25%TIAUSDT-6.14%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-1.70%GRTUSDT-4.15%WIFUSDT-4.80%POLUSDT+0.48%IOTAUSDT-5.89%AXSUSDT-3.31%FARTCOINUSDT-1.65%EOSUSDT-4.51%DYDXUSDT-5.98%ORDIUSDT-2.12%GALAUSDT-1.47%NOTUSDT-0.18%RONINUSDT-14.59%NVDA+0.53%AAPL-0.87%GOOGL-1.59%MSFT-0.95%AMZN-1.89%TSM-0.99%SPCX-1.90%META+1.06%AVGO-0.96%TSLA+0.45%SKHY-0.24%BRK-B-0.01%LLY+0.55%MU+0.59%JPM-1.36%WMT-0.14%AMD+1.97%V-0.45%XOM+2.27%JNJ-0.98%ASMLa-1.22%0700.HK+1.90%MA-0.61%INTC+1.07%ABBV+0.31%1398.HK-2.09%CSCO+0.62%CVX+1.81%BAC-0.33%ORCL-1.01%COST-1.10%KO-0.98%DELL+3.86%CAT-0.38%HSBA.L-2.08%0005.HK-3.21%PG+0.41%UNH-1.56%LRCX-2.25%AP2d-2.19%AMAT-1.10%1816.HK-0.46%3988.HK-2.13%NFLX-2.73%GE-2.73%MS-1.88%0857.HK+0.60%HD-1.47%PM-0.25%0939.HK-2.83%USDJPY+1.02%NZDUSD-0.94%CHFJPY+0.78%USDTHB+0.71%GBPJPY+0.69%CADJPY+0.68%GBPNZD+0.64%NZDCHF-0.62%NZDCAD-0.61%AUDUSD-0.57%EURJPY+0.51%EURUSD-0.48%AUDJPY+0.47%EURNZD+0.47%PLNJPY+0.44%NOKJPY+0.43%GBPTRY+0.41%AUDNZD+0.38%USDCAD+0.33%NZDMXN-0.33%USDCHF+0.33%GBPHKD+0.32%SGDJPY+0.32%GBPUSD-0.31%GBPMXN-0.28%USDTRY+0.25%GBPAUD+0.24%AUDCHF-0.23%AUDCAD-0.22%USDSEK+0.21%USDSGD+0.19%EURCAD-0.17%USDILS+0.16%EURSEK+0.16%EURGBP-0.15%NZDSGD-0.15%EURCHF-0.14%EURSGD+0.14%GBPZAR-0.14%CHFNOK-0.13%EURCZK+0.11%EURAUD+0.10%USDNOK+0.08%AUDDKK-0.08%NZDJPY+0.08%USDCNH+0.07%USDPLN+0.07%GBPSGD+0.07%EURZAR-0.07%AUDSGD+0.06%AUDNOK-0.05%USDDKK+0.05%EURHKD-0.04%USDCOP-0.04%GBPCAD+0.03%EURNOK+0.03%CHFSGD-0.02%CADCHF-0.02%USDHKD+0.02%USDMXN+0.02%EURPLN+0.02%USDZAR-0.01%EURDKK-0.01%CHFSEK-0.01%EURCNH0.00%GBPCHF0.00%USOIL+2.54%W1+1.74%UKOIL+1.60%SUGAR-1.49%XNGUSD+1.25%COFFEE-1.07%COCOA-1.02%C1+1.01%S1+0.89%HG1+0.42%XAUUSD-0.30%GAUUSD-0.30%BTCUSD-2.73%ETHUSD-4.03%USDTUSD-0.03%XRPUSD-2.45%SOLUSD-3.23%TRXUSDT-0.44%ZECUSDT-3.95%DOGEUSD-2.29%XMRUSDT+0.75%LINKUSD-2.60%XLMUSD+0.50%BCHUSDT-1.43%UNIUSD-3.14%LTCUSD-2.62%HBARUSDT-0.18%TONUSD+26.79%SUIUSD-2.62%TAOUSDT-3.30%AAVEUSD-2.37%DOTUSDT-2.21%ICPUSDT-7.23%ONDOUSDT-3.37%WLDUSDT-1.56%ARBUSDT+4.73%ATOMUSDT-1.85%JUPUSDT-4.30%INJUSDT-9.68%STXUSDT-3.11%FETUSDT-4.35%PYTHUSDT-4.25%TIAUSDT-6.14%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-1.70%GRTUSDT-4.15%WIFUSDT-4.80%POLUSDT+0.48%IOTAUSDT-5.89%AXSUSDT-3.31%FARTCOINUSDT-1.65%EOSUSDT-4.51%DYDXUSDT-5.98%ORDIUSDT-2.12%GALAUSDT-1.47%NOTUSDT-0.18%RONINUSDT-14.59%
XB

Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ • Healthcare

$7.57
+$0.12 (+1.6%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$7.6
Previous Close$7.57
Day Range$7.52 - $7.69
Avg. Volume (3M)1.6M
Market Cap$1.2B
52 Week Range
$5.25$10.08
Next EarningsIn 51 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$92.1M100%
Gross Profitminus cost of goods$79.5M86%
Operating Incomeminus R&D and overhead$5.1M6%

In plain terms: out of every $100 in revenue, Xeris Biopharma Holdings, Inc. currently loses $34.

Fundamentals & Financials

Revenue (TTM)
$335.4M
Net Income (TTM)
-$17.1M
EPS (TTM)
-$0.097
ROA (TTM)
-4.17%
Current Ratio
1.45

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+100.0%Q1 2026$0.06
+465.0%Q2 2026$0.01
-1582.7%Q3 2026-$0.18
Next

Nov 5

in 51 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -1582.7%

Revenue rose 28.7% to roughly $92.1 million in Xeris Biopharma’s second fiscal quarter of 2026, based on preliminary results reported August 6, 2026, with revenue of $92.1 million in line with the $90.1 million estimate (+2.2%) and up from about $71.5 million a year ago. Gross profit was roughly $79.6 million, translating to a gross margin of about 86%, while operating income came in around $5.2 million and operating margin stood near 6%. The quarter generated operating cash flow of about $8.3 million, and the company repurchased roughly $0.2 million of stock. Consensus for the next period calls for EPS of $0.02 on revenue of $101.6 million.

View full earnings history

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. develops and commercializes specialty therapies in biotechnology, centered on endocrinology, neurology, and gastroenterology, and generated $291.8 million of revenue in FY2025. The NASDAQ-listed company, traded as XERS, builds its portfolio around proprietary formulation technologies and a focused set of marketed products.

Name
Xeris Biopharma Holdings, Inc.
CEO
John Shannon
Website
www.xerispharma.com
Industry
Healthcare
Year Founded
2005
Employees
435

Today's Snapshot

AI-generated

The session opened with XERS flat at 7.57, while its sector was flat.

Trading Volume

Below 10d avg (1.6M)

144.2K

vs S&P 500 Today

Underperforming Market

-0.81%

Updated: September 15, 2026 at 14:32 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
XERS shows a sell bias with short-term momentum readings deep in oversold territory but longer momentum and MACD remaining negative, leaving the picture skewed to the downside. The stock trades below most short- and medium-term moving averages while remaining above some longer-term averages, and ADX near 19.22 indicates little trend conviction. Volatility is modest with an ATR near 0.35, and the pivot sits above the current price, adding near-term resistance. Technical takeaway: Sell bias — internal momentum is weak and short-term moving averages act as resistance.
All signals
  • EMA (5 indicators)$7.57 - $8.14
    Sell
  • RSI (14)32.50
    Neutral
  • Stochastic %K (14, 3, 3)6.86
    Buy
  • MACD Level (12, 26)-0.19
    Sell

Peers & Related Assets

CLDXCelldex Therapeutics, Inc.
$39.18+6.2%
VERAVera Therapeutics, Inc.
$34.05-2.9%
HRMYHarmony Biosciences Holdings, Inc.
$41.54+0.1%
BCRXBioCryst Pharmaceuticals, Inc.
$8.23+1.4%
BHVNBiohaven Ltd.
$12.64-0.6%
MAZEMaze Therapeutics, Inc.
$24.67+0.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.